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Two highly pathogenic human coronaviruses associated with severe respiratory syndromes emerged
since the beginning of the century. The severe acute respiratory syndrome SARS-coronavirus (CoV)
spread ﬁrst in southern China in 2003 with about 8000 infected cases in few months. Then in 2012, the
Middle East respiratory syndrome (MERS-CoV) emerged from the Arabian Peninsula giving a still on-
going epidemic associated to a high fatality rate. CoVs are thus considered a major health threat. This
is especially true as no vaccine nor speciﬁc therapeutic are available against either SARS- or MERS-CoV.
Therefore, new drugs need to be identiﬁed in order to develop antiviral treatments limiting CoV repli-
cation. In this study, we focus on the nsp14 protein, which plays a key role in virus replication as it
methylates the RNA cap structure at the N7 position of the guanine. We developed a high-throughput
N7-MTase assay based on Homogenous Time Resolved Fluorescence (HTRF®) and screened chemical
libraries (2000 compounds) on the SARS-CoV nsp14. 20 compounds inhibiting the SARS-CoV nsp14 were
further evaluated by IC50 determination and their speciﬁcity was assessed toward ﬂavivirus- and human
cap N7-MTases. Our results reveal three classes of compounds: 1) molecules inhibiting several MTases as
well as the dengue virus polymerase activity unspeciﬁcally, 2) pan MTases inhibitors targeting both viral
and cellular MTases, and 3) inhibitors targeting one viral MTase more speciﬁcally showing however
activity against the human cap N7-MTase. These compounds provide a ﬁrst basis towards the devel-
opment of more speciﬁc inhibitors of viral methyltransferases.
© 2017 Published by Elsevier B.V.1. Introduction
The severe acute respiratory syndrome coronavirus (SARS-CoV)
spread in China in 2003 and was responsible for worldwide
outbreak causing over 8000 infected people with a fatality rate
around 10% (de Wit et al., 2016). In 2012, a novel human corona-
virus named Middle East Respiratory Syndrome Coronavirus
(MERS-CoV) emerged in the Arabian Peninsula with secondary
infection cases reported in Europe, America, Asia and Africa. MERS-(E. Decroly).CoV infection resulted in more than 1728 conﬁrmed infected pa-
tients till April 2016 with a fatality rate of 36% (de Wit et al., 2016).
CoVs are enveloped viruses possessing a single stranded posi-
tive sense RNA genome of approximately 29.7 kb in length (Pan
et al., 2008; Van Boheemen et al., 2012). The SARS-CoV initiates
its replication cycle after binding to the angiotensin-converting
enzyme 2 (ACE2) (Kuhn et al., 2004). After endocytosis, the viral
RNA genome is released into the cellular host cytoplasm and
translated into two large polyproteins (de Wit et al., 2016; Snijder
et al., 2016). The pp1a and pp1ab polyproteins are next cleaved
by viral proteases into 11 and 16 non-structural proteins respec-
tively (nsp1 to 16). These proteins form a large replication tran-
scription complex (RTC) which is associated to host cellular
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of the viral genome and the transcription of genomic and sub-
genomic mRNA. These viral RNAs are polyadenylated at their 30
end and protected by a 50 cap structure, which is synthetized by
viral enzymes. The CoV capping pathway is thought to follow four
sequential steps implicating several nsps: I) the 50-30 helicase/
NTPase nsp13 hydrolyses ﬁrst the phosphate g from the nascent 5’-
triphosphorylated RNA (Ivanov and Ziebuhr, 2004); II) a GMP
molecule is supposedly transferred to the diphosphorylated RNA by
a still unknown guanylyltransferase forming a cap (GpppN) struc-
ture; III) the cap is then methylated at N7 position of the guanosine
by nsp14 in the presence of methyl donor S-adenosyl-L-methionine
(SAM) yielding to a cap-0 (7mGpppN) and S-adenosyl-L-homocys-
teine (SAH) by-product (Chen et al., 2009); IV) nsp10/nsp16 com-
plex methylates at the ribose 20OH group of the ﬁrst transcribed
RNA leading to the conversion of the cap-0 (7mGpppN) into the cap-
1 (7mGpppN2’om) (Bouvet et al., 2010; Chen et al., 2011). In vitro
assays have deciphered the mechanisms driving the RNA cap
methylation in SARS- and MERS-CoV. It follows an obligatory order
in which N7-methylation by nsp14 is a pre-requisite for 20O-
methylation by the nsp10/nsp16 complex (Aouadi et al., 2017;
Bouvet et al., 2014, 2010).
The guanine N7-MTase activity embedded in the C-terminal
domain of SARS-nsp14 has been discovered by yeast trans-
complementation assay (Chen et al., 2009). In addition, the N-ter-
minus moiety of nsp14 contains a DEDDh exonuclease (ExoN)
domain (Minskaia et al., 2006). The two domains communicate
functionally, as truncation experiments showed that the N-termi-
nal region of nsp14 is required for the N7-MTase activity (Chen
et al., 2009). Both N7-MTase and ExoN activities have been
conﬁrmed by in vitro assay showing that the association of nsp10 to
nsp14 stimulated >35 fold the ExoN activity while the N7-MTase
activity does not depend on the nsp10-nsp14 interaction (Bouvet
et al., 2012, 2010; Decroly et al., 2011).
The N7- and 20O- methylations of the viral mRNA cap are key
events for the viral infection. Indeed reverse genetic experiments
revealed ﬁrst that the N7- methylation of cap structures is essential
for the synthesis of viral proteins (Case et al., 2016). This observa-
tion is corroborated by former biochemical data showing that the
N7-methyl guanosine of cap structures is recognized by the
eukaryotic translation initiation factor 4E (eIF4E) and participates
in the initiation of viral mRNA translation into proteins (Case et al.,
2016; Cougot et al., 2004). Accordingly, inhibitors blocking nsp14
N7-MTase activity have been identiﬁed by yeast based screening
assay on SARS-CoV, and induced a potent antiviral effect demon-
strating that nsp14 MTase activity is an attractive antiviral target
(Sun et al., 2014). Whereas N7-MTase mutants are replication
defective, 20O-MTase mutants show limited effect on virus repli-
cation in cell culture but have an attenuated phenotype in animal
models (Li et al., 2013; Menachery et al., 2014; Zhang et al., 2014;
Züst et al., 2013). The molecular basis of this attenuated pheno-
type was recently elucidated: incompletely-capped RNAs have
been shown to be recognized by immune sensors such as RIG-I and
MDA-5, which trigger innate immunity pathways (Decroly et al.,
2012; Schuberth-Wagner et al., 2015; Wu et al., 2013). In turn,
RIG-I or MDA-5 induces signalling cascades yielding to the
expression of cytokines and type I interferon inducing an antiviral
state in neighboring cells. Among the interferon-stimulated gens
(ISG), IFIT1 also participates to the restriction of viral replication by
sequestrating mis-capped viral RNAs (Pichlmair et al., 2011). Thus
cap structure is now considered as a kind of “marker of self” and it is
currently admitted that 20O-MTase inhibitors might help virus
clearance by stimulation of the immune response (Decroly et al.,
2012; Ferron et al., 2012; Züst et al., 2011).
In this work we ﬁrst developed an HTRF MTase assay in order toidentify compounds inhibiting the N7-MTase activity of SARS-CoV
nsp14. Using this system, we screened a library composed of
2000 compounds containing 1280 FDA approved molecules (Pre-
stwick Chemical Library®), 320 natural products and 400
pyridazine-derived compounds. The inhibitory effect of the 20 best
compounds was conﬁrmed by a radioactive ﬁlter-binding assay,
and reﬁned by IC50 values determination on SARS nsp14 and hu-
man RNA N7-MTase (hRNMT). In addition, the speciﬁcity of each
compound was further evaluated using the CoV 20O-MTase (nsp10/
nsp16) and theMTases of Dengue andWest-Nile ﬂaviviruses as well
as the hRNMT involved in the capping of cellular RNAs.
2. Materials and methods
2.1. Description of the libraries
The Prestwick Chemical Library® is a unique collection of 1280
small molecules, mostly approved drugs (FDA, EMA and other
agencies) selected for their high chemical and pharmacological
diversity as well as for their known bioavailability and safety in
humans. The Prestwick Phytochemical Library is a collection of 320
natural products, mostly derived from plants, assembled by me-
dicinal chemists and rich in diverse chemotypes, thus realistic for
follow-up chemistry. The Prestwick Pyridazine Library is a collec-
tion of 400 innovative pyridazine and pyridazone derivatives, based
on a series of carefully selected neworiginal scaffolds. All molecules
have been designed to ensure optimal diversity, and are suitable for
diverse chemical modiﬁcation.
2.2. Expression and puriﬁcation of recombinant proteins
The viral MTases (SARS-CoV nsp14, MERS-CoV nsp14, DENV-3
NS5-MTase, West Nile virus NS5-MTase, DENV-2 NS5-RdRp and
human RNA N7-methyltransferase (RNMT) coding sequences were
cloned in fusion with a N-terminus hexa-histidine tag in Gateway®
plasmids (pDest14 or pDest17, Life technologies). The proteins were
expressed in E. coli cells and puriﬁed following previously
described protocols (Aouadi et al., 2017; Bouvet et al., 2010; Ma
et al., 2015; Milhas et al., 2016; Peyrane et al., 2007; Selisko et al.,
2006). MERS-CoV nsp14 was produced and puriﬁed as follows:
the protein were expressed in Arctic Express E. coli strain (Agilent)
at 13 C during 24 h after addition of 50 mM IPTG. The bacteria were
pelleted (13,000 g, 4 C, 5 min), and lysed by sonication in
appropriate buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5%
glycerol, 20 mM imidazole, 5 mM b-mercaptoethanol, 1 mM PMSF,
10 mg/ml DNase-I and 0.25 mg/ml lysozyme). After clariﬁcation
(50,000 g, 30 min at 4 C) the recombinant protein was puriﬁed
by immobilized metal afﬁnity chromatography (IMAC) on 1 ml of
HisPurTM Cobalt Resin (Thermo Scientiﬁc) followed by size exclu-
sion chromatography on a Superdex 200 (GE healthcare) equili-
brated in (30 mM HEPES pH (7.5), 300 mM NaCl and 5% glycerol).
The puriﬁed proteins were analyzed on SDS-PAGE gels after Coo-
massie blue staining (Fig. 1 and Fig. S1).
2.3. HTRF screen on SARS CoV nsp14 MTase
For the initial screening, 400 nl of each compound resuspended
in 100% DMSO at 1 mMwere dispensed in the reaction volume (5%
ﬁnal DMSO, 50 mM compound) using a Mosquito Crystal pipetting
robot platform (TTP labtech). DMSO, sinefungin (20 mM) and SAH
(2 mM) were used as controls.
The enzymatic reaction was performed in 8 ml. 3 ml of mix
(Buffer þ SARS nsp14 at 5 nM ﬁnal concentration) were added in
the assay wells, containing previously dispensed inhibitors (0.4 ml),
using a Biomek NX MC pipetting robot (Beckman). The reaction
Fig. 1. Characterization of the recombinant SARS-CoV nsp14. A) 2.5 mg of SARS-CoV
nsp14 on a 10% SDS-PAGE gel stained by Coomassie blue. MW, molecular size markers.
B) Bar graph representing the N7-MTase activity of SARS-nsp14 determined by
monitoring the transfer of tritiated methyl from [3H] SAM onto GpppA and 7mGpppA.
The tritiated RNA was quantiﬁed by DEAE ﬁlter binding assay (FBA).
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ﬁnal concentrations). Reaction was started with 4.6 ml of a mix
containing both GpppA (NEB ref S1406) and SAM at 8 mM and 2 mM
ﬁnal concentrations respectively and was incubated 20 min at
30 C.
For the detection of released SAH, the EPIgeneous™ methyl-
transferase kit was purchased from CisBio Bioassays and recon-
stituted according to the supplier protocols. HTRF assays were
performed in white 384 Well Small Volume™ HiBase Polystyrene
Microplates (Greiner) with a ﬁnal volume of 20 ml. 2 ml of EPIge-
neous detection buffer one and 2 ml of NaCl 5 Mwere then added in
order to stop the reaction. After 10 min of incubation at room
temperature, detection reagents were added: 4 ml of a 1/16 dilution
of SAH conjugated to the ﬂorescent dye d2 in a ﬁrst place then 4 ml
of Anti-SAH antibody-Lumi4-Tb at a 1/150 dilution. HTRF signals
were measured, after a 1 h ﬁnal incubation at room temperature,
using a PHERAstarFS (BMG Labtech) with an excitation ﬁlter at
337 nm and ﬂuorescence wavelength measurements at 620 and
665 nm, an integration delay of 60 ms and an integration time of 400
ms. Results were analyzed with a two-wavelength signal ratio:
[intensity (665 nm)/intensity (620 nm)]*104 (HTRF Ratio). The
normalized HTRF ratio is calculated as follow: [(compound signal) -
(min signal)]/[(max signal) - (min signal)] * 100, where 'max signal'
is the signal ratio without protein and 'min signal' the signal ratio
with DMSO in place of compound.
The Z0 factor is calculated using the following equation: Z0 ¼ 1 e
[3(SD of max) þ 3(SD of min)]/[(mean max signal) - (mean min
signal)], where SD is the standard deviation. For IC50 measure-
ments, values were normalized and ﬁtted with Prism (GraphPad
software) using the following equation: Y ¼ 100/(1 þ ((X/IC50)^ Hill
slope)).
The initial screening assay was performed once and the hits
were then conﬁrmed by determination of IC50 (HTRF) in quadrupli-
cates. IC50 (HTRF) is deﬁned as the compound concentration for
which the SAH release is decreased by 50%.2.4. MTase ﬁlter binding assay (FBA)
The inhibitor speciﬁcity assays were carried out in reaction
mixture [40 mM Tris-HCl (pH 8.0), 1 mM DTT, 1 mM MgCl2, 2 mM
SAM, and 0.33 mM 3H-SAM (Perkin Elmer)] in the presence of
0.7 mM GpppAC4 or 7mGpppAC4 synthetic RNAs. Puriﬁed SARS-
nsp14 (10 nM), MERS-nsp14 (250 nM), SARS-nsp10/nsp16 (1 mM),
MERS-nsp10/nsp16 (500 nM), hRNMT (20 nM), DENV-MT (500 nM)
andWNV NS5 (500 nM). The enzymes were mixed ﬁrst with 50 mM
inhibitors before the addition of RNA substrate and SAM and then
incubated at 30 C. The ﬁnal concentration of DMSO was 5%, and
control reactions were performed in the presence of 5% DMSO.
Reaction mixtures were stopped after 30 min by their 10-fold
dilution in ice-cold 100 mM SAH. Samples were transferred to
Diethylaminoethyl cellulose ﬁlters (DEAE) (Perkin Elmer) using a
Filtermat Harvester apparatus (Packard Instruments). The unin-
corporated 3H SAMwas removed from the ﬁlter by several washing
with 0.01 M ammonium formate pH (8.0), H2O, then absolute
ethanol, before drying of the DEAE ﬁlters. The ﬁlters were incu-
bated with BetaplateScint (Wallac) scintillation ﬂuid before quan-
tiﬁcation of 3Hmethylation transferred onto RNA substrates using a
Wallac 1450 MicroBetaTriLux liquid scintillation counter in counts
per minute (cpm).
The inhibition speciﬁcity of DV-2 RdRp was performed using
100 nM enzyme, 200 mM ATP, 4 mM [3H] ATP and 100 nM polyU
substrate into the buffer reaction [50 mMHEPES,10mMDTT, 5 mM
MgCl2, 2 mM MnCl2]. The reaction was incubated during 10 min at
30 C then stopped by adding 100 mM EDTA ﬁnal concentration.
The reaction mixture was then transferred onto DEAE ﬁlter as
described above. The unincorporated [3H]ATP during the RNA
synthesis was removed from the ﬁlter with 0.2 M ammonium
formate as described above. The IC50 values of inhibitors on SARS-
nsp14 and RNMT were determined using 0.35 mM GpppAUAU RNA
mimicking the 50 extremity of SARS-CoV genome and 0.35 mM
GpppAC4 for hRNMT. The IC50 values were ﬁtted as described
above.
3. Results
3.1. Expression of active SARS-CoV nsp14 N7 MTase
SARS-CoV encodes the bi-functional enzyme nsp14, which
contains an N-terminal ExoN domain followed by a N7-MTase
domain involved in RNA capping. The recombinant protein was
puriﬁed by immobilized metal afﬁnity chromatography (IMAC)
followed by size exclusion chromatography. The puriﬁed nsp14 is
detected as a single bandmigrating at the expected molecular mass
(Fig. 1A, z60 kDa) on Coomassie blue stained SDS-PAGE gels. The
puriﬁed nsp14 transfers [3H] methyl onto a GpppA cap analogue
whereas no MTase activity is detected onto 7mGpppA (Fig. 1B)
indicating that nsp14 harbors an N7-MTase activity that can be
detected using cost effective commercial cap analogues.
3.2. Optimization of HTRF assay for high-throughput screening
We miniaturized the EPIgenous MTase assay based on Homog-
enous Time Resolved Fluorescence (HTRF) (Degorce et al., 2009) to
screen a library of 2000 compounds. The principle of the HTRF
assay, shown in Fig. S2, is to follow the MTase activity by indirectly
detecting SAH, the by-product of the methyl transfer reaction.
Indeed, in the detection system, the released SAH competes with
ﬂuorescent SAH-d2, which binds to an anti-SAH antibody coupled
to a cryptate ﬂuorophore (see Material and Methods). Thus, in-
crease of SAH leads to decrease of the HTRF signal (Fig. S3D). The
experimental conditions for the enzymatic assay were optimized
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concentration was set up at 5 nM of nsp14 as titration curves
indicated that 80% of the maximal activity after 20 min incubation
period is obtained at this enzyme concentration (Fig. S3A); II)
GpppA substrate concentration was adjusted at 8 mM to robustly
and reproducibly detect N7-MTase activity (Fig. S3B); III) SAM
concentration was adjusted to 2 mM in order to ensure the optimal
conversion rate of SAM to SAH according to the manufacture rec-
ommendations (z4e11%, Fig. S3C/D). The SAH detection condi-
tions were optimized and the SAH-d2 and anti-SAH antibody were
diluted 1/16 and 1/150 respectively.
Fig. 2A shows the time course experiment of nsp14 MTase ac-
tivity indicating that using our experimental optimized conditions
the N7-methylation reaction reached the saturation phase after a
30 min incubation period. The enzymatic reactions were thus
incubated during 20 min in the screening. Sinefungin, which has
already been reported to inhibit the SARS-CoV N7-MTase
(IC50 z 500 nM) (Bouvet et al., 2010), was used as positive con-
trol for MTase inhibition. The inhibition curve of nsp14MTase using
the optimized HTRF assay revealed an inhibition in a similar range,
with IC50 (HTRF) value of 110 nM (Fig. 2B). We also assessed that the
addition of DMSO up to 5% did not impact the MTase reactions and/
or the HTRF quantiﬁcation of released SAH. The signal variationwas
estimated to 2e2.8%. The average of Z0 value was 0.69.Fig. 2. HTRF assay validation using SARS-nsp14. A) Time course analysis of SARS-CoV
nsp14 MTase activity by HTRF assay: 0 or 5 nM of nsp14 (empty or full triangles,
respectively) are incubated with 8 mM GpppA and 2 mM SAM at 30 C for increasing
time periods. The reaction by-product (SAH) was quantiﬁed by measuring the ratio of
emission and excitation ﬂuorescence at 665 and 620 nm, on a PolarStar reader as
described in materials and methods. B) Sinefungin IC50 (HTRF) determination. Increasing
concentrations of sinefungin (0e0.5 mM) were incubated with 5 nM nsp14, 2 mM SAM,
8 mMGpppA at 30 C during 20 min and the SAH by-product was detected as described
in panel A. The IC50 (HTRF) was then calculated using graphPad Prism equation (n ¼ 3;
Mean value ± SD).3.3. HTRF screening of inhibitors against SARS-CoV nsp14 N7-
MTase activity
The chemical library containing 1280 FDA approved molecules,
320 natural substrates and 400 pyridazine derived compounds was
used for initial screening at 50 mM of each compound and the in-
hibition was determined using HTRF assay. Compounds showing
inhibition of the MTase activity higher than 42%, which corre-
sponds to increase of the HTRF signal >20% (Fig. S4), were ﬁrst
selected (41 compounds, Fig. 3). 21 compounds were discarded due
to signal interference with the HTRF assay or by visual inspection.
The 20 remaining compounds (hit rate 0.1%, Table 1) were selected
for IC50 (HTRF) determination by HTRF. The results presented in
Table 1 indicate that the IC50 (HTRF) vary from 0.16 to > 400 mM,
among which 4 have an IC50 (HTRF) higher than 75mM. IC50 (HTRF) for
1159, 597, 194 were not determined due to intrinsic ﬂuorescence
interferences at high concentration. Thus, 13 compounds show IC50
(HTRF) ranging from 0.16 to 75 mM.Fig. 3. Distribution of inhibition percentage values obtained by HTRF screening on
Prestwick Chemical libraries. The 2000 compounds were screened at 50 mM, 5%
DMSO on SARS CoV nsp14 MTase activity using HTRF assay (5 nM nsp14, 8 mM GpppA,
2 mM SAM, SAH-d2 (1/16) and anti-SAH (1/150)). The grey line corresponds to an in-
crease of 20% of the HTRF signal that was used as a threshold for the selection of the
primary hits.
Table 1
Screening results and IC50 (HTRF) of selected compounds on the SARS-nsp14 by HTRF
assay.
Compounds HTRF signal increase at 50 mM (%) IC50 (HTRF) (mM)
152 51.4 171.5 ± 16
792 50 5.8 ± 2
210 42.5 17.1 ± 5.6
909 41 >400
545 34.8 >400
1159 33.9 Not available
602 33.3 73.6 ± 29
1426 32.7 0.16 ± 0.02
1040 30.8 5.5 ± 1
1298 29.4 2 ± 0.6
1305 29 3.3 ± 0.7
604 27.9 57.2 ± 15
597 26.8 Not available
1418 25.4 18.9 ± 3.8
925 25 5 ± 0.6
1207 22.8 73 ± 9.3
312 21.8 38.6 ± 5
194 21.8 Not available
752 21.5 35.5 ± 7.3
1434 20 >400
Sinefungin 96.9 0.112 ± 0.01
Not available: IC50 (HTRF) not accurate due to ﬂuorescence issues at high compound
concentrations.
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nsp14
In order to validate the inhibition observed by HTRF, we next
performed a radioactive MTase assay (FBA) using freshly solubilized
compounds. In this experiment, the MTase activity was analyzed by
measuring the [3H] radiolabeled methyl transferred onto a longer
synthetic RNA substrate (GpppAC4). This capped RNA was previ-
ously evidenced as a better substrate for nsp14 N7-MTase than the
cap analogue GpppA (Bouvet et al., 2010). The low inhibition of theTable 2
Inhibition speciﬁcity of compounds at 50 mM on MTases and DENV-2 polymerase activit
The compounds are clustered and framed according to their inhibition speciﬁcity from w4 compounds showing IC50 (HTRF) > 75 mM by HTRF (1434, 152, 545,
909), was conﬁrmed by the FBA assay. In addition the ﬂuorescent
compounds 194, 597 poorly inhibits the MTase activity in this FBA
assay. Finally, eleven compounds display a potent inhibition (>80%)
at 50 mM concentration using the radioactive assay (Table 2).
Whereas we observed some discrepancies between HTRF and FBA
assay for a couple of compounds (210 and 909), which could be
explained by the difference in RNA substrate length used in both
assays; we observed a good correlation between both assays.ies using DEAE-ﬁlter binding assay.
ide range to speciﬁc inhibitors. ND: Not determined.
Table 4
Evaluation of compound 312 analogs. IC50 determined by FBA on SARS-CoV nsp14
and RNMT MTase activities using GpppAC4 substrate.
Compounds Structure IC50 (mM) on
SARS nsp14 RNMT
312 7.3 ± 0.4 14.3 ± 1
457 6.2 ± 0.4 8.8 ± 0.6
278 9.1 ± 0.7 16.8 ± 2
1264 13.5 ± 2 13.7 ± 0.8
133 No inhibition 365.2 ± 186
510 No inhibition 159 ± 36
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cellular MTases
The speciﬁcity of the 20 compounds was then analyzed by
measuring their inhibition proﬁle on other viral and cellular MTases
(for more details see workﬂow in Fig. S5). We thus produced and
puriﬁed the SARS- and MERS-CoV nsp14 and the nsp10/nsp16
complex (20O-MTase); the full length NS5 of the West Nile (WNV)
and NS5-MTase domain of Dengue 3 (DENV-3) viruses and the
human RNA N7-MTase (hRNMT) (Fig. S1) in order to compare their
inhibition proﬁle. The inhibition of each compound (50 mM) was
then determined by FBAMTase activity measurements. In addition,
we also tested whether the DENV-2-RdRp activity is inhibited in
order to address the compound speciﬁcity. The results summarized
in Table 2 show that among the 11 best SARS-CoV nsp14 inhibitors
conﬁrmed by FBA (Table 5), 5 (925, 1426, 1298, 1305, 1159) show
large spectrum inhibition as they inhibit all testedMTases as well as
the DENV-2 RdRp. Table 2 also reveals that sinefungin (used as
positive control) and compound 1040 exhibit a broad spectrum
MTase inhibition proﬁle with no inhibition detected on the RdRp
activity of DENV NS5. This broad-spectrum inhibition observed
with sinefungin has already been reported and can be related to its
structural homology with the SAM/SAH (Dong et al., 2010). Inter-
estingly, compound 792 inhibits mainly the CoV N7- and 20O-
MTase as well as the hRNMT but barely interferes with DENV-3 or
WNV NS5 MTase activity. Finally, the four last compounds (312,
1418,1207, 604) showmore speciﬁc inhibition proﬁle onMERS- and
SARS-CoV nsp14 although they inhibit the hRNMT.
To further characterize the eleven most potent nsp14 N7-MTase
inhibitors, a dose response curve was performed with the com-
pounds showing percentage inhibition higher or equal to 40%
against SARS-CoV nsp14 and the hRNMT. After pre-incubationwith
increasing concentrations of inhibitors, the MTase activity was
followed by FBA. The IC50 of compounds on either nsp14 or hRNMT
activities ranged from 19 nM to 23 mM and 50 nM to 5.5 mM,
respectively, conﬁrming the observed inhibition potency of these
molecules (Table 3). In addition, the IC50 values determined in this
assay corroborate with those performed by HTRF assay (Table 1).
The broad spectrumMTase inhibitor (1040) shows IC50 values of 4.5
and 5.1 mMon SARS nsp14 and human hRNMT respectively and four
compounds targeting more speciﬁcally SARS, MERS and hRNMT
have IC50 values between 10 and 24 mM, but IC50 values observed
with for hRNMT are lower in each case.
Altogether these results suggest that structural homology be-
tween viral and cellular MTases might impair the discovery of in-
hibitors targeting speciﬁcally the CoV N7-MTase (see discussion
about homology). Nevertheless, we also observed that the less
active inhibitors on SARS-CoV nsp14 barely inhibit the humanTable 3
Comparison of the IC50 value of 11 most active compounds on SARS-nsp14 and
human RNMT activities using GpppAUAU and GpppAC4 substrates respectively.
Compounds IC50 SARS-nsp14 (mM) IC50 RNMT (mM)
Sinefungin 0.36 ± 0.08 <0.05
925 1.5 ± 0.11 1 ± 0.1
1426 0.019 ND
1298 0.74 ± 0.1 0.32 ± 0,27
1305 1.3 ± 0.2 0.4 ± 0.05
1040 4.5 ± 0.35 5.1 ± 2.28
792 31 ± 3 5.5 ± 1.92
1159 2 ± 0.44 <0.05
312 12.3 ± 1 4.84 ± 1.6
1418 23.7 ± 7 10 ± 3
1207 18.4 ± 2 ND
604 11 ± 1 1.28 ± 0.16
ND: Not Determined.hRNMT suggesting the possibility to identify more speciﬁc MTase
inhibitors (Table 2). A structure activity relationship (SAR) study is
required in order to gain in activity and speciﬁcity.
3.6. Inhibition of SARS-CoV nsp14 by compound 312 analogs
already present in the library
Following the conﬁrmation of compound 312, analogs were706 No inhibition 226.8 ± 29
503 No inhibition 102.2 ± 21
Table 5
Structure of the most active compounds.
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for inhibition of SARS nsp14 and hRNMT MTase activities by FBA
(Table 4). All the 7 analogs bear the benzhydryl-piperazine group
characteristic to this chemical series in the right-hand side of the
structure. Four compounds lacking the aromatic moiety in the left
part of the molecule show no inhibition of SARS-CoV nsp14 MTase.
In contrast, 3 analogs carrying an aromatic terminal ring in the left-
hand side inhibit the SARS-CoV N7-MTase activity with IC50 be-
tween 6.2 and 14 mM (457, 278 and 1264). The substitution of the
two phenyl rings in the benzhydryl-piperazine moiety (ﬂuorine or
chlorine groups) have no impact on the inhibition proﬁle. These
compounds were initially not selected from the original screening
but their inhibition was close to the selection cut-off (42% inhibi-
tion at 50 mM). The compounds inhibited the hRNMTand SARS-CoV
nsp14 to similar levels. Although they did not bring additional
speciﬁcity compared to compound 312, it might be worth sampling
a larger chemical space within this family.
4. Discussion
The identiﬁcation of molecules inhibiting viral enzymes essen-
tial for virus replication is a key point to combat emerging viruses.
Methylations of viral mRNA cap structures are an essential step in
the virus life-cycle (Case et al., 2016; Cougot et al., 2004) preventing
their identiﬁcation as foreign RNA markers by the host cell
(Diamond, 2014; Li et al., 2013; Züst et al., 2013). Thus, enzymes
such asMTases involved in viral RNA capping are nowconsidered as
promising antiviral targets (Ferron et al., 2012). Here, we developed
a high-throughput MTase screening assay based on HTRF technol-
ogy that possesses advantageous features. The HTRF assay allows
the minimization of non-speciﬁc ﬂuorescence emissions by intro-
ducing a time delay (50e150 ms) between the initial light excitation
and ﬂuorescence measurement (Degorce et al., 2009). This time
delay limits the interference of ﬂuorescent compounds in the
screening assay. Indeed, only 37 out of 2000 compounds interfered
with the detection system among which were considered as 17
false positive. In addition, a non-ﬂuorescent enzymatic assay (FBA)
was used to conﬁrm the hits obtained from the primary screening.
The initial screening was performed using a commercial cap
analogue substrate (GpppA), as the availability of high amount of
capped RNA substrates is a limiting step. This screening allowed the
identiﬁcation of 20 compounds inhibiting at least 42% of the nsp14
N7-MTase activity. The inhibitory effect (below 25 mM, Table 3) of
11 of these compounds was conﬁrmed using a radioactive ﬁlter-
binding assay performed with longer synthetic RNA substrates
(GpppAC4). In contrast, 9 compounds barely inhibited the MTase
activity measured with GpppAC4 substrate. Thus, it is likely that the
use of GpppA as substrate may favor the identiﬁcation of inhibitors
that would be less efﬁcient on longer RNA substrates. The weaker
inhibition effect observed using longer RNA substrates might sug-
gest that these compounds interfere with the RNA binding site of
the enzyme.
One important issue in the drug discovery process is to identify
compounds inhibiting speciﬁcally the viral enzymes but barely
active on the cognate cellular enzymes in order to limit their
cytotoxicity or off-target effects. To determine the compound
speciﬁcity at the early stage of the screening process, we compared
the inhibition activity of the 20 compounds on other viral MTases
(SARS- andMERS-CoV 20OMTase, DEN-V andWNV N7/20OMTases)
and a cellular MTase hRNMT involved in the methylation of cap
structures. In addition, we also tested these compounds on the
Dengue virus polymerase in order to control the inhibition speci-
ﬁcity on the RdRp activity and eliminate molecules showing un-
speciﬁc inhibition or frequent hitters. This strategy revealed that 5
out of the 11 best hits identiﬁed in the nsp14 N7-MTase activity-screening campaign potently inhibited all MTases tested as well
as the Dengue virus polymerase.
We also observed that most inhibitors identiﬁed in this
comparative screening potently inhibit the human RNA N7-MTase
hRNMT (12 over 20 compounds). These results might be related
to structural and functional homologies between CoV N7-MTase
and the human hRNMT limiting the possibility to identify in-
hibitors targeting speciﬁcally the CoV N7-MTase. However, we
would like to propose that the inhibitors identiﬁed here might well
be substratemimicks and bind to conserved substrate pockets since
the protein folding of hRNMT and nsp14 are signiﬁcantly different,
the latter deviating from classical Rossman-fold MTases. It is also
noteworthy that this work was performed with a highly active
truncated construct of hRNMT, which is used at very low concen-
tration (20 nM) for IC50 determination. Additionally, it is also
possible that as our truncated hRNMT is less selective as it lacks the
hRNMTactivating Miniprotein (RAM) binding domain and the RAM
protein. Indeed it was previously demonstrated that RAM stabilizes
the structure and positioning of the hRNMT lobe and increases the
speciﬁc recruitment of SAM (Varshney et al., 2016). This high in-
hibition of hRNMTMTase activity may be overcome in the presence
of its allosteric activator RAM, which may allow to stringent the
speciﬁcity of the compounds.
Out of nsp14, the comparative screening using various MTases
also reveals that several compounds show a large spectrum of
MTase inhibition without any signiﬁcant activity detected on the
Dengue virus polymerase used as a control (compounds 1040 and
the positive control sinefungin). The pleiotropic inhibition
observed on MTases activities suggests that despite the weak pri-
mary sequence conservation, these enzymes do have a common
structural organization (Rosmann fold characteristic of most of viral
and cellular MTases) and share similar enzymatic properties. This
observation is consistent with the common structural organization,
with a conserved SAM, RNA and/or cap binding sites, shared by
those MTases. The identiﬁcation of broad-spectrum viral MTases
inhibitors may offer a starting point to develop new antiviral
compounds. We considered that these molecules could be inter-
esting as we expected that the SAR process will give the opportu-
nity to increase both speciﬁcity and inhibition properties.
Accordingly, a SAR study previously performed on the ﬂavivirus
MTases has demonstrated that chemical analogs of SAH, showed
improved activity and selectivity against DENV MTase, but not on
the related human enzymes (Lim et al., 2011). The crystal structure
revealed that the most active SAH derivative harbors substitutions
accommodated in a speciﬁc cavity conserved in Flaviviral MTases. It
would be thus relevant to initiate the structural analysis of viral
MTases in complex with the best compounds in order to improve
selectivity.
5. Conclusion
Viral N7- and 20O-MTase is now considered as promising anti-
viral target as their inhibition is supposed to impair mRNA trans-
lation into viral proteins and to induce the stimulation of the innate
immune system of the infected host. Thus it is currently accepted
that MTase inhibitors might help virus clearance by stimulation of
the immune response (Decroly et al., 2012; Ferron et al., 2012; Züst
et al., 2011). In this work we identiﬁed 20 molecules inhibiting the
N7-MTase activity of SARS-CoV nsp14 from chemical libraries
composed of 2000 compounds using an HTRF based inhibition
assay. Eleven compounds demonstrated a potent inhibition (>80%)
at 50 mM concentration using the radioactive assay. The speciﬁcity
of each compound was further evaluated using a radioactive assay
on CoV 20O-MTase (nsp10/nsp16) and the MTases of Dengue and
West-Nile viruses as well as the human RNA N7-MTase (hRNMT)
W. Aouadi et al. / Antiviral Research 144 (2017) 330e339338involved in the capping of cellular RNAs. This comparative analysis
revealed that the selected compounds cluster in 3 classes: 1) barely
speciﬁc inhibitors, 2) pan-MTases inhibitors inhibiting viral and
cellular MTases, 3) inhibitors targeting more speciﬁcally one viral
MTase but also active against the hRNMT. These latter series of
inhibitors may represent a good starting point for the development
of antivirals targeting the CoV MTases.
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